Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.30 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188625 | 1.00 | TMEM97 (0.32) | TMEM97SMYD3RENPARP1 | |
| SCHEMBL6281965 | 1.00 | TMEM97 (0.32) | TMEM97SMYD3RENPARP1 | |
| SCHEMBL5188359 | 1.00 | TMEM97 (0.32) | TMEM97SMYD3RENPARP1 | |
| SCHEMBL6281723 | 0.91 | TMEM97 (0.31) | TMEM97REN | |
| SCHEMBL6279101 | 0.91 | TMEM97 (0.31) | TMEM97REN | |
| SCHEMBL6283611 | 0.91 | TMEM97 (0.31) | TMEM97REN | |
| SCHEMBL6278815 | 0.91 | TMEM97 (0.31) | TMEM97REN | |
| SCHEMBL6302745 | 0.88 | TMEM97 (0.31) | TMEM97SMYD3PARP1 | |
| SCHEMBL5471671 | 0.88 | CA14 (0.40) | SMYD3 | |
| SCHEMBL6302937 | 0.87 | TMEM97 (0.31) | TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282610-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-6914059-B2 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2005-07-05 | — | — | US | disclosed |
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2004-01-08 | — | — | US | disclosed |
| EP-1282610-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001081323-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | CYP4Z1, XDH, CYP3A5 | TMEM97 2100/4885SMYD3 4551/4885REN 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.